![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Acadia Wins FDA Priority Review for Psychosis Drug
Acadia Wins FDA Priority Review for Psychosis Drug
![](https://www.fdanews.com/ext/resources/test/Device_Images4/FDA_Logo_Large.gif?t=1486528488&width=430)
November 6, 2015
The FDA has granted priority review to Acadia Pharmaceuticals’ Nuplazid for the treatment of psychosis associated with Parkinson’s disease. A PDUFA date has been set for May 1, 2016.
The NDA submission includes data from a pivotal Phase 3 study that showed improvement in both primary and secondary endpoints with no worsening of motor function.
Nuplazid (pimavanserin) acts as a selective serotonin inverse agonist that targets 5-HT2A receptors.
Upcoming Events
-
21Oct